These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19734806)

  • 21. Restoration of hematopoiesis after iron chelation therapy with deferasirox in 2 children with severe aplastic anemia.
    Koh KN; Park M; Kim BE; Im HJ; Seo JJ
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):611-4. PubMed ID: 20881872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paradoxically increased ferritin level in a beta-thalassemia major patient following the start of deferasirox chelation therapy.
    Ricchi P; Ammirabile M; Spasiano A; Costantini S; Cinque P; Di Matola T; Prossomariti L
    Acta Haematol; 2010; 123(2):117-20. PubMed ID: 20068283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia.
    Lee SE; Yahng SA; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Kim HJ; Cho SG; Kim DW; Min WS; Park CW; Lee JW
    Acta Haematol; 2013; 129(2):72-7. PubMed ID: 23154600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term efficacy and safety of deferasirox.
    Cappellini MD
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxidative stress and antioxidant capacity in sickle cell anaemia patients receiving different treatments and medications for different periods of time.
    Belini Junior E; da Silva DG; Torres Lde S; de Almeida EA; Cancado RD; Chiattone C; Bonini-Domingos CR
    Ann Hematol; 2012 Apr; 91(4):479-89. PubMed ID: 21947087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.
    Metzgeroth G; Dinter D; Schultheis B; Dorn-Beineke A; Lutz K; Leismann O; Hehlmann R; Hastka J
    Ann Hematol; 2009 Apr; 88(4):301-10. PubMed ID: 18758781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fanconi syndrome in a patient with β-thalassemia major after using deferasirox for 27 months.
    Wei HY; Yang CP; Cheng CH; Lo FS
    Transfusion; 2011 May; 51(5):949-54. PubMed ID: 21077910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacoeconomic benefits of deferasirox in the management of iron overload syndromes.
    Imran F; Phatak P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):297-304. PubMed ID: 19670988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
    Ladis V; Berdousi H; Gotsis E; Kattamis A
    Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.
    Greenberg PL; Koller CA; Cabantchik ZI; Warsi G; Glynos T; Paley C; Schiffer C
    Leuk Res; 2010 Dec; 34(12):1560-5. PubMed ID: 20615548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report.
    Panigrahi I; Vaidya PC; Bansal D; Marwaha RK
    J Pediatr Hematol Oncol; 2012 Jan; 34(1):51-3. PubMed ID: 22215098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis.
    Qadah T
    J Int Med Res; 2022 Dec; 50(12):3000605221143290. PubMed ID: 36562113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observational study comparing long-term safety and efficacy of Deferasirox with Desferrioxamine therapy in chelation-naïve children with transfusional iron overload.
    Aydinok Y; Unal S; Oymak Y; Vergin C; Türker ZD; Yildiz D; Yesilipek A
    Eur J Haematol; 2012 May; 88(5):431-8. PubMed ID: 22335829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
    Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
    Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis.
    Messa E; Cilloni D; Messa F; Arruga F; Roetto A; Saglio G
    Acta Haematol; 2008; 120(2):70-4. PubMed ID: 18827475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Barriers to adherence of deferoxamine usage in sickle cell disease.
    Treadwell MJ; Law AW; Sung J; Hackney-Stephens E; Quirolo K; Murray E; Glendenning GA; Vichinsky E
    Pediatr Blood Cancer; 2005 May; 44(5):500-7. PubMed ID: 15602707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox.
    Aleem A; Shakoor Z; Alsaleh K; Algahtani F; Iqbal Z; Al-Momen A
    J Coll Physicians Surg Pak; 2014 Jul; 24(7):467-71. PubMed ID: 25052967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferasirox-induced renal impairment in children: an increasing concern for pediatricians.
    Dubourg L; Laurain C; Ranchin B; Pondarré C; Hadj-Aïssa A; Sigaudo-Roussel D; Cochat P
    Pediatr Nephrol; 2012 Nov; 27(11):2115-2122. PubMed ID: 22527533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.